Therapeutics

JNJ-40346527

Overview

Name: JNJ-40346527
Synonyms: Edicotinib, JNJ-527, PRV-6527
Chemical Name: 5-cyano-N-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1H-imidazole-2-carboxamide
Therapy Type: Small Molecule (timeline)
Target Type: Inflammation (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 1)
Company: Janssen

Background

JNJ-40346527 is an oral, selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase (for details, see on MedChemExpress). CSF-1R ligands promote survival, proliferation, and differentiation of macrophages and microglia; they also spur the growth of some cancers.

In Alzheimer’s disease, activation and proinflammatory cytokine release by microglia are essential mediators of pathology. This has spurred interest in drugs targeting microglial receptors.

JNJ-40346527 was tested in mouse models of prion disease and tauopathy (Mancuso et al., 2019). In the prion mice, the drug entered the brain and inhibited proliferation of microglia. In transgenic mice expressing human P30-1L tau, JNJ-40346527 blocked microglia proliferation and the production of the cytokines IL1β and TNFα. It reduced tau phosphorylation and neurodegeneration in the spinal cord, improved motor skills, and normalized the gene expression profile of microglia.

Findings

In March 2020, Janssen and the University of Oxford registered a Phase 1 trial in people with mild cognitive impairment. The biomarker-based study will evaluate if JNJ-40346527 treatment changes CSF-1R signaling and microglia status. Three U.K. sites will enroll 54 participants with a Clinical Dementia Rating of 0.5 and randomize them 2:1 to receive 300 mg JNJ-40346527 twice daily or placebo for two weeks. Primary outcome is change in the concentration of CSF-1R ligands in cerebrospinal fluid. Secondary measures include unspecified biomarkers in CSF and plasma, CSF levels of microglia-derived extracellular vesicles and cells, CSF and plasma JNJ-40346527 levels, and safety assessments.

Depending on the results after two weeks of treatment, the trial will continue into a second randomized phase, at a dose to be determined. The trial will end in November 2020.

JNJ-40346527 was originally evaluated in cancer, arthritis, and inflammatory bowel disease, and has been tested extensively in people. It proved ineffective in Phase 2 trials for rheumatoid arthritis (Genovese et al., 2015) and Hodgkin’s lymphoma (von Tresckow et al., 2015).

In October 2019, JNJ-40346527 was reported to have been safe and well-tolerated but fallen short of primary endpoint in a trial for Crohn’s disease (press release, FierceBiotech story). Trials are ongoing in prostate cancer and acute myeloid leukemia.

For details on JNJ-40346527 trials, see clinicaltrials.gov.

Last Updated: 17 Apr 2020

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

Research Models Citations

  1. hTau.P301S

Paper Citations

  1. . Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. J Rheumatol. 2015 Oct;42(10):1752-60. Epub 2015 Aug 1 PubMed.
  2. . An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50. Epub 2015 Jan 27 PubMed.
  3. . CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain. 2019 Oct 1;142(10):3243-3264. PubMed.

External Citations

  1. press release
  2. FierceBiotech story
  3. clinicaltrials.gov
  4. MedChemExpress)

Further Reading

Papers

  1. . The CSF-1-receptor inhibitor, JNJ-40346527 (PRV-6527), reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis. PLoS One. 2019;14(11):e0223918. Epub 2019 Nov 11 PubMed.
  2. . Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications. Biomed Pharmacother. 2018 Jul;103:662-679. Epub 2018 Apr 24 PubMed.